WGS: Customer Conversion And Market Expansion Will Shape Rare Disease Diagnostics

Analysts have raised their price target for GeneDx Holdings from $127.22 to $151.22 per share. They cite strong quarterly execution and sustained growth driven by successful customer conversions and new market expansions.

Narrative Update on GeneDx Holdings Analysts have raised their price target for GeneDx Holdings from $123.75 to $127.22. This change reflects improved expectations for revenue growth and profit margins in upcoming periods.

Analyst price targets for GeneDx Holdings have been raised as bullish sentiment grows around its first-mover advantage in rare disease testing, strengthening demand outlook from new medical guidance and early profitability signs, with the consensus target increasing slightly from $121.25 to $123.75. Analyst Commentary Bullish analysts highlight GeneDx's position as a fast grower in the under-penetrated rare disease testing market.

Analysts have raised GeneDx Holdings’ price target from $115.29 to $121.25, citing accelerating growth in rare disease testing, a first-mover advantage, expected boost from new pediatric testing guidelines, and a recent shift to profitability as key drivers. Analyst Commentary Bullish analysts highlight GeneDx’s fast growth in the under-penetrated rare disease testing market.

Analysts have raised their price target for GeneDx Holdings from $104.61 to $113.86, citing the company's accelerating growth and first-mover advantage in rare disease diagnostics, a looming profitability inflection, and favorable shifts in pediatric testing standards. Analyst Commentary Bullish analysts highlight GeneDx as a fast-growing player in the under-penetrated rare disease testing market.